Physician profile
Eric Schubert
NPI 1275594467
$3,597.36
in general payments reported to CMS, 2019-2025
20 companies · $54.07 in 2025
The $54.07 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,390 · 2020: $40.37 · 2021: $333 · 2022: $255 · 2023: $195 · 2024: $1,331 · 2025: $54.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955 · Travel and Lodging: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.25 |
| Travel and Lodging | $624.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,149.04 | 2022-2024 | Everest Spinal System, N/A, Sonopet Iq |
| Si-Bone, INC. | $854.21 | 2019-2021 | |
| Medtronic USA, INC. | $611.67 | 2019 | |
| Boston Scientific Corporation | $333.85 | 2023-2025 | Wavewriter Alpha Prime 16, Spectra Wavewriter |
| Zimmer Biomet Holdings, INC. | $130.61 | 2021 | |
| Abbvie INC. | $97.28 | 2022-2024 | |
| Amgen INC. | $50.77 | 2019 | |
| Novo Nordisk INC | $49.02 | 2021 | |
| Axsome Therapeutics, INC. | $48.47 | 2023 | Auvelity |
| Edwards Lifesciences Corporation | $40.67 | 2024 | Sapien 3 Ultra Resilia |
| Glaxosmithkline, LLC. | $37.59 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Nuvasive, INC. | $34.37 | 2019 | |
| Lundbeck LLC | $34.16 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $25.36 | 2023 | Ninlaro |
| Grifols USA, LLC | $22.78 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $18.99 | 2022 | |
| Merck Sharp & Dohme LLC | $16.58 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.47 | 2021 | |
| Neurocrine Biosciences, INC. | $13.33 | 2024 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $13.14 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Schubert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.